CRISPR-Edited Stem Cells Could Make Blood-Cancer Therapy Safer
On 25th September 2026, researchers reported results from a phase 1/2 clinical trial in which donor blood stem cells were edited using CRISPR-Cas9 to remove the protein CD33, potentially allowing aggressive blood cancers to be targeted while sparing healthy blood-forming cells.
How Does the Technology Work?
- CD33 Targeting Challenge: In diseases such as acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), CD33 is present on cancer cells as well as healthy myeloid cells. Thus, CD33-targeted therapies may damage healthy blood cells along with cancer cells.
- CRISPR-Cas9 Gene Editing: Researchers genetically modified donor haematopoietic stem cells before transplantation so that the healthy ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Already a Member? Login here
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Science & Technology
- 1 MIT Builds ‘Living Transistors’ from Engineered Bacteria
- 2 Peptide Biomaterials Could Power Future Medical Implants
- 3 GSLV-F17 Successfully Launches EOS-05
- 4 Magnetar Offers Strongest Evidence Yet for ‘Non-Empty’ Space
- 5 Aditya-L1 Detects Early Warning Signs of Solar Flares
- 6 GalaxEye to Develop Indigenous OptoSAR Earth-Observation Satellite
- 7 IAF Successfully Tests Indigenous Long-Range Glide Bomb Khagantak-243
- 8 Brain Circuit Linked to Chemotherapy-Induced Cold Allodynia
- 9 RAKSHA Framework to Guide India’s Defence Diplomacy
- 10 India to Acquire US Javelin Anti-Tank Missiles
